# Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study（TOPS-CSVD）

Study · id `cardio:ct-nct06061692` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06061692](<https://clinicaltrials.gov/study/NCT06061692>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06061692

Browse, organ or system: Blood vessels; Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1052 participants.

## Technical summary

Registry record NCT06061692. Randomized; quadruple masking; primary purpose treatment. Start 2023-10 (anticipated); primary completion 2026-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1052 participants (planned count; ClinicalTrials.gov record NCT06061692, source copy `cardio:ctgov-nct06061692-2023-09-29`, retrieved 2026-11-18)
- Planned start: 2023-10 (anticipated) (ClinicalTrials.gov record NCT06061692, source copy `cardio:ctgov-nct06061692-2023-09-29`, retrieved 2026-11-18)
- Primary completion: 2026-06 (anticipated) (ClinicalTrials.gov record NCT06061692, source copy `cardio:ctgov-nct06061692-2023-09-29`, retrieved 2026-11-18)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06061692, source copy `cardio:ctgov-nct06061692-2023-09-29`, retrieved 2026-11-18)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06061692-2023-09-29`, retrieved 2026-11-18)

## The registry's words

- Brief title: Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study（TOPS-CSVD）
- Condition: Cerebral Small Vessel Diseases
- Intervention (Drug): Tongxinluo Capsule
- Lead sponsor: Fudan University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cerebral small vessel disease (`cardio:cerebral-small-vessel-disease`)
- Registry lists this organization as the lead sponsor: Fudan University (`cardio:org-fudan-university`)

## Provenance

Content hash: 4c5b47af548cdc9efb1e0f08b54afb7138f199ede906a70b9841535a5c2f9861
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
